Core--IMMUNOGENETICS OF HUMAN DIABETES

核心--人类糖尿病的免疫遗传学

• 批准号: 7468456
• 负责人: LEROY E HOOD
• 金额: $ 10.15万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7468456
• 关键词: Academic Medical Centers; African; Arts; Childhood; Chromosome Mapping; Core Facility; DNA Sequence; Diabetes Mellitus; France; Genetic; HLA-DQ Antigens; HLA-DR Antigens; Home environment; Institutes; Insulin-Dependent Diabetes Mellitus; Laboratories; Monoclonal Antibodies; Proteins; Proteomics; Research; Research Personnel; Resolution; SNP genotyping; Scientist; Services; Universities; Visit; high throughput technology; human leukocyte antigen gene; medical schools; programs

The objective of the Core B facility is to provide expertise and a state of the art facility for large scale, high-resolution genetic mapping, DNA sequencing and state of the art proteomics. The core facility will provide HLA-DQ and HLA-DR typing for all the projects in the program and will perform high throughput SNP genotyping on type 1 diabetes candidate loci other than HLA genes (project 4). Suggestive results will be typed in other projects for confirmation. We will also provide sequencing services for the characterization of GAD65 monoclonal antibodies (project 2) and proteomics analysis for the identification of antigenic proteins in type 1 and type 1.5 diabetes (project 3). These high throughput technologies will aid the program project investigators to determine the genetic, environmental and immunological features which can help predict and cure type 1 diabetes.

Core B 设施的目标是为大规模、高分辨率遗传图谱、DNA 测序和最先进的蛋白质组学提供专业知识和最先进的设施。核心设施将为该计划中的所有项目提供 HLA-DQ 和 HLA-DR 分型，并将对 HLA 基因以外的 1 型糖尿病候选位点进行高通量 SNP 基因分型（项目 4）。建议的结果将被输入到其他项目中进行确认。我们还将提供用于表征 GAD65 单克隆抗体的测序服务（项目 2）以及用于鉴定 1 型和 1.5 型糖尿病抗原蛋白的蛋白质组学分析（项目 3）。这些高通量技术将帮助该项目的研究人员确定遗传、环境和免疫学特征，从而帮助预测和治愈 1 型糖尿病。